| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44045731 | HTLV-1 | ENSG00000184408.10 | protein_coding | KCND2 | No | No | 3751 | A4D0V9 Q9NZV8 |
| TVIS44039684 | HTLV-1 | ENSG00000184408.10 | protein_coding | KCND2 | No | No | 3751 | A4D0V9 Q9NZV8 |
| TVIS44045730 | HTLV-1 | ENSG00000184408.10 | protein_coding | KCND2 | No | No | 3751 | A4D0V9 Q9NZV8 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KCND2 |
|---|---|
| DrugBank ID | DB06637 |
| Drug Name | Dalfampridine |
| Target ID | BE0003603 |
| UniProt ID | Q9NZV8 |
| Regulation Type | antagonist |
| PubMed IDs | 23184313 |
| Citations | Goodman AD, Stone RT: Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy). Neurotherapeutics. 2013 Jan;10(1):106-10. doi: 10.1007/s13311-012-0156-3. |
| Groups | Approved |
| Direct Classification | Aminopyridines and derivatives |
| SMILES | NC1=CC=NC=C1 |
| Pathways | |
| PharmGKB | PA166123389 |
| ChEMBL | CHEMBL284348 |
